Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/
US: CAFC confirms PTO is miscalculating (undercalculating) delays in prosecution and the corresponding patent term adjustment: Wyeth v Kappos (Patently-O) (GRAY On Claims) (Inventive Step) (IP Factor) (Patent Docs) (Patent Docs) (IP Spotlight) (IP Law Blog)
Cipramil (Citalopram) – EU: Commission opens antitrust investigation into pharmaceutical company Lundbeck (EPLAW) (Managing IP) (GenericsWeb)
Do patents impede medical care and innovation? (Michael Geist)
Bolivia: Bolivian Government to launch pharma company that will provide traditional indigenous medicine (IP tango)
Bolivia: Tougher sanctions against counterfeit medicines (IP tango)
EU: Patent harmony in Europe – Olanzapine (IP Think Tank)
EU: Commission launches monitoring of pharmaceutical patent settlements (EPLAW) (IPKat)
EU: GSK CEO appointed as new EFPIA president (Managing IP)
EU: The SPC Blog Seminar: Martijn de Lange’s presentation (SPC blog)
India: NUJS I(P)DEATE Series: Graham Dutfield on Traditional medicines and IP (Spicy IP)
India to lead efforts in negotiation protocol on access and benefit sharing (Spicy IP)
India: Is section 3(d) jeopardising innovation? Madras High Court decision in Novartis Glivec case (Patentcircle)
Israel: State of Israel sues Omrix for NIS 500 million, claiming core technology is based on service inventions. Have they killed the golden goose? (IP Factor)
Netherlands: Court of Appeal, The Hague: Costs of procedure : Lundbeck v Tiefenbacher, Centrafarm Services and Ratiopharm (EPLAW)
Poland: First judgment on differences between sponsorship and advertising of pharmaceutical product (Class 46)
US: USPTO to begin recalculating patent term following Wyeth v Kappos (Patently-O) (Patent Docs)
US: CAFC confirms PTO is miscalculating (undercalculating) delays in prosecution and the corresponding patent term adjustment: Wyeth v Kappos (Patently-O) (GRAY On Claims) (Inventive Step) (IP Factor) (Patent Docs) (Patent Docs) (IP Spotlight) (IP Law Blog)
US: PTO responds in gene patent saga (Inventive Step)
US: Drug label established intent to induce although the drug was prescribed for non-infringing use and the label was required by the FDA: Eli Lilly and Company v. Actavis Elizabeth LLC (Docket Report)
US: Inclusion of Pay-for-Delay ban in Health Care Bill urged; FTC to hold press conference announcing pay-for-delay analysis (FDA Law Blog)
Cipramil (Citalopram) – EU: Commission opens antitrust investigation into pharmaceutical company Lundbeck (EPLAW) (Managing IP) (GenericsWeb)
Hectorol (Doxercalciferol) – US: Genzyme files patent infringement complaint against Cobrek in N D Illinois following Para IV challenge: Genzyme Corp. v. Cobrek Pharmaceuticals, Inc (Patent Docs)
Nexium (Esomeprazole) – US: Teva drops patent challenge following settlement agreement with AstraZeneca over Nexium (IP Factor) (GenericsWeb)
Nuvigil (Armodafinil) – US: Mylan confirms first-to-file patent challenge relating to sleep-disorder drug (SmartBrief)
Nuvigil (Armodafinil) – US: Cephalon sues Watson for patent infringement following Para IV challenge (Patent Docs) (GenericsWeb) (Patentcircle)
Tasigna (Nilotinib) – India: Novartis receives patent for second-line CML therapy drug (Patentcircle)